William J Welch
CIK 1237522 · Chief Executive Officer · last filed 2018-02-01
William J Welch is a Chief Executive Officer who has filed 22 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for TROV, was dated Feb 1, 2018. Across all open-market trades the lifetime net is +$46.4K, making them a net buyer over the disclosed history. 6 SEC filings were submitted jointly with LA JOLLA PHARMACEUTICAL CO.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SQNM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Cardiff Oncology, Inc. (TROV) Delisted | Chief Executive Officer | 904,655 | — | — | $0 | 5 | 2018-02-01 |
| Cardiff Oncology, Inc. (TROVW) Delisted | CEO | 2,500 | — | — | $9.9K | 3 | 2017-04-10 |
| SEQUENOM INC (SQNM) Delisted | President & CEO | 56,060 | — | — | $36.5K | 10 | 2015-06-11 |
| Monogram Biosciences, Inc. (MGRM) Delisted | SVP, Chief Commercial Officer | — | $6.00 | — | $0 | 4 | 2009-01-22 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-02-01 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +67,990 | $0 | EDGAR |
| 2018-01-25 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-04 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +24,513 | $0 | EDGAR |
| 2018-01-04 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +24,513 | $0 | EDGAR |
| 2017-08-17 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | +745,392 | $0 | EDGAR |
| 2017-04-10 | Cardiff Oncology, Inc. (TROVW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-04 | Cardiff Oncology, Inc. (TROVW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-19 | Cardiff Oncology, Inc. (TROVW) Delisted | Buy (P) | +4,750 | $9.9K | EDGAR |
| 2015-06-11 | SEQUENOM INC (SQNM) Delisted | Mixed | +3,433 | -$6.9K | EDGAR |
| 2015-03-11 | SEQUENOM INC (SQNM) Delisted | Buy (P) | +10,000 | $36.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.